Giritinib or venetoclax, which one is better in terms of efficacy?

Comparing the efficacy of giritinib and venetoclax is a complex issue because it involves multiple factors, including the patient's condition, genetic mutations, treatment options, etc.

Giritinib is the first approved FLT3 inhibitor, mainly used to treat relapsed or refractory acute myeloid leukemia (AML) carrying FLT3 mutations. FLT3mutations account for about 30% of AML, and the prognosis of these patients is usually poor. Giritinib can significantly inhibit the proliferation of leukemia cells by inhibiting the FLT3 signaling pathway. In clinical trials, giritinib has shown significant efficacy in patients with FLT3 mutation-positive AML. For example, in a phase III clinical trial, 21% of patients achieved hematological complete or partial response after oral administration of gilitinib. In addition, giritinib improved the patient's median overall survival from 5.6 months to 9.3 months.

Venetoclax is a BCL-2 inhibitor originally approved to treat chronic lymphocytic leukemia (CLL ). However, studies in recent years have found that it also has a significant effect in the treatment of AML, especially when combined with hypomethylating drugs or other chemotherapy drugs. In the treatment of AML, the combination of venetoclax and other drugs has shown high efficacy. For example, the combination therapy of venetoclax and giritinib has achieved remarkable results in FLT3wild-typeAML patients, of which 84% achieved high bone marrow and peripheral blood blast cell clearance rates. This data is significantly higher than the efficacy of single agent giritinib.

ForFLT3mutation-positiveAMLpatients, giritinib is an effective treatment option and its efficacy has been demonstrated in clinical trials.

Venetoclax has also shown significant efficacy in the treatment ofAML, especially when combined with other drugs. In FLT3wild-type AML patients, the combination therapy of venetoclax and giritinib has achieved impressive results.

Therefore, giritinib and venetoclax each have advantages in terms of efficacy. Which one is better depends on the patient's specific condition and genetic mutations. When choosing a treatment plan, the doctor will conduct a comprehensive assessment based on the patient's specific situation.